Strides Pharma Science Limited (NSE:STAR)
India
· Delayed Price · Currency is INR 898.75
+11.40 (1.28%)
Jun 27, 2025, 3:29 PM IST
Strides Pharma Science Revenue
In the fiscal year ending March 31, 2025, Strides Pharma Science had annual revenue of 45.65B INR with 12.69% growth. Strides Pharma Science had revenue of 11.90B in the quarter ending March 31, 2025, with 9.81% growth.
Revenue
45.65B
Revenue Growth
+12.69%
P/S Ratio
1.81
Revenue / Employee
14.90M
Employees
3,065
Market Cap
82.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 45.65B | 5.14B | 12.69% |
| Mar 31, 2024 | 40.51B | 3.63B | 9.83% |
| Mar 31, 2023 | 36.88B | 6.18B | 20.13% |
| Mar 31, 2022 | 30.70B | -2.46B | -7.41% |
| Mar 31, 2021 | 33.16B | 5.64B | 20.49% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Strides Pharma Science News
- 2 months ago - Strides Pharma receives USFDA approval for Celecoxib Capsules - Business Upturn
- 2 months ago - Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation - Business Upturn
- 5 months ago - Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25 - Business Upturn
- 5 months ago - Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY - Business Upturn
- 5 months ago - Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio - Business Upturn
- 8 months ago - Strides Pharma Science Q2 FY25 Results: Net profit surges to ₹93.7 crore, US revenues hit historic high - Business Upturn
- 9 months ago - OneSource raises Rs 801 crore from investors, boosts growth for Strides shareholders - Business Upturn
- 10 months ago - Strides Pharma shares surge 3% on USFDA nod for Fluoxetine Tabs 60 mg - Business Upturn